Cumberland Pharmaceuticals Announces Top-Line Results from Phase 2a ASSIST-SSc Trial

Cumberland Pharmaceuticals Inc. announced top-line results from its Phase 2a ASSIST-SSc trial for its oral ifetroban product candidate, which was found to be generally well-tolerated with a safety profile consistent with previous studies. The trial focused on safety and tolerability in patients with systemic sclerosis but was not designed to evaluate efficacy, limiting definitive conclusions. The company has consulted with clinical experts regarding the results from both the dcSSc and SSc-PAH cohorts.